Cancer Cell Therapy

Multiple Myeloma

Newly Diagnosed

CCT5077
Phase III Randomized Study Comparing DdiR followed by Citacabtagene Autoleucel vs DdiR followed by Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma who are Transplant Eligible
PI: Sidana Sponsor: Janssen Research & Development, LLC

CCT5107
Phase II Multicohort Open-Label Study of JNJ-68284528 a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in Newly Diagnosed Multiple Myeloma
PI: Sidana Sponsor: Janssen Research & Development, LLC

Post-Auto

CCT504
Phase II Anti-CD38 Cell Maturation in Multiple Myeloma in Sub-Optimal Response After Autologous Hematopoietic Cell Transplantation and Maintenance Lenalidomide
PI: Sidana Sponsor: BMT CTN

CCT507
Phase I Open-Label Dose-Finding Study of BMS-986453 Dual Targeting BCMAxGPRC5D Chimeric Antigen Receptor T Cells, in Relapsed and/or Refractory Multiple Myeloma
PI: Sidana Sponsor: Celgene Corporation

Relapsed

CCT505
Expanded Access Protocol (EAP) in Ib/decabtagene Vicklucel that is Non-conforming for Commercial Release
PI: Sidana Sponsor: Janssen Research & Development, LLC

Auto

CCT5056
Intermediate-Size Population Expanded Access Program (EAP) for Citacabtagene Autoleucel (Cila-Cel) Out-of-Specification (OOS) in Multiple Myeloma
PI: Sidana Sponsor: Janssen Research & Development, LLC

Note: CCT5059 closes when CCT5091 opens